Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore the latest advancements in HPV testing through this 44-minute webinar that examines new ASCCP guidelines for extended genotyping and self-collection methods. Learn about the BD Onclarityâ„¢ HPV Assay, the first FDA-approved test that individually identifies 6 genotypes and is cited in clinical management guidelines for positive HPV results. Discover how extended genotyping enhances patient care standards and supports more precise cervical cancer prevention strategies. Understand the significance of the new CPT code for HPV tests incorporating DNA testing and extended genotyping, and gain insights into proper coding practices for capturing new reimbursement rates. Examine the unique combination of extended genotyping capabilities and FDA approval for self-collection in healthcare settings that BD Onclarityâ„¢ offers. Review health economic considerations and reimbursement information while understanding the responsibilities of healthcare providers in determining medical necessity and submitting appropriate claims. Participate in live Q&A sessions with expert presenters including moderator Molly Broache, MSN, WHNP-BC, along with Ibtihaj Awadelkariem and Brittany Nesbitt to address specific questions about implementation and clinical applications of these emerging HPV testing methods.
